CorporateProfile

Forte Biosciences is a clinical-stage biopharmaceutical company whose lead product candidate is FB102. FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. The Company’s FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. A phase 1 healthy volunteer SAD/MAD study was successfully completed and demonstrated a good safety profile. The Company initiated patient-based studies in celiac disease in the third quarter of 2024.

Learn More

Latest Press releases

RecentEvents

All Events

FeaturedPresentation